Ortin Laboratories Limited
Ortin Global Limited engages in the manufacture and trading of pharmaceuticals, drugs, and intermediates in India. The company offers various pharmaceutical formulations of tablets, capsules, syrups, and dry powders. It provides formulations, such as anti-diabetics, anti allergics, sedatives and tranquilisers, anti helmenthetics, analgesics and antipyretics, anti-biotics-quinolones, anti-biotic-p… Read more
Ortin Laboratories Limited (ORTINLAB) - Total Assets
Latest total assets as of March 2024: ₹66.64 Million INR
Based on the latest financial reports, Ortin Laboratories Limited (ORTINLAB) holds total assets worth ₹66.64 Million INR as of March 2024.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Ortin Laboratories Limited - Total Assets Trend (2009–2024)
This chart illustrates how Ortin Laboratories Limited’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Ortin Laboratories Limited - Asset Composition Analysis
Current Asset Composition (March 2024)
Ortin Laboratories Limited's total assets of ₹66.64 Million consist of 95.2% current assets and 4.8% non-current assets.
| Asset Category | Amount (INR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₹0.00 | 35.2% |
| Accounts Receivable | ₹17.66 Million | 26.5% |
| Inventory | ₹502.00K | 0.8% |
| Property, Plant & Equipment | ₹0.00 | 0.0% |
| Intangible Assets | ₹0.00 | 0.0% |
| Goodwill | ₹0.00 | 0.0% |
Asset Composition Trend (2009–2024)
This chart illustrates how Ortin Laboratories Limited's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Ortin Laboratories Limited's current assets represent 95.2% of total assets in 2024, an increase from 77.3% in 2009.
- Cash Position: Cash and equivalents constituted 35.2% of total assets in 2024, up from 25.1% in 2009.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2009.
- Asset Diversification: The largest asset category is accounts receivable at 26.5% of total assets.
Ortin Laboratories Limited Competitors by Total Assets
Key competitors of Ortin Laboratories Limited based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF
|
USA | $67.26 Billion |
|
Kamada
NASDAQ:KMDA
|
USA | $378.79 Million |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Kotra Industries Bhd
KLSE:0002
|
Malaysia | RM363.90 Million |
Ortin Laboratories Limited - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Ortin Laboratories Limited generates 0.32x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Ortin Laboratories Limited is currently not profitable relative to its asset base.
Ortin Laboratories Limited - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.11 | 0.94 | 1.14 |
| Quick Ratio | 3.09 | 0.56 | 0.62 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | ₹43.07 Million | ₹ -4.44 Million | ₹ 98.65 Million |
Ortin Laboratories Limited - Advanced Valuation Insights
This section examines the relationship between Ortin Laboratories Limited's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 5.65 |
| Latest Market Cap to Assets Ratio | 0.02 |
| Asset Growth Rate (YoY) | -68.6% |
| Total Assets | ₹66.64 Million |
| Market Capitalization | $1.22 Million USD |
Valuation Analysis
Below Book Valuation: The market values Ortin Laboratories Limited's assets below their book value (0.02 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Ortin Laboratories Limited's assets decreased by 68.6% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Ortin Laboratories Limited (2009–2024)
The table below shows the annual total assets of Ortin Laboratories Limited from 2009 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-03-31 | ₹66.64 Million | -68.56% |
| 2023-03-31 | ₹211.97 Million | +2.38% |
| 2022-03-31 | ₹207.05 Million | -2.64% |
| 2021-03-31 | ₹212.66 Million | -81.75% |
| 2020-03-31 | ₹1.17 Billion | +10.88% |
| 2019-03-31 | ₹1.05 Billion | +42.66% |
| 2018-03-31 | ₹736.63 Million | +19.95% |
| 2017-03-31 | ₹614.09 Million | -6.01% |
| 2016-03-31 | ₹653.36 Million | -2.87% |
| 2015-03-31 | ₹672.68 Million | -7.30% |
| 2014-03-31 | ₹725.67 Million | -1.26% |
| 2013-03-31 | ₹734.92 Million | -11.51% |
| 2012-03-31 | ₹830.54 Million | +52.21% |
| 2011-03-31 | ₹545.67 Million | +275.93% |
| 2010-03-31 | ₹145.15 Million | -2.53% |
| 2009-03-31 | ₹148.91 Million | -- |